Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT00732810 | SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | completed | Phase 2 | 97 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 5, 2015 | clinicaltrials |
| NCT00632931 |
| A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) |
| completed |
| Phase 1 |
| 25 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Jul 30, 2015 |
| clinicaltrials |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | terminated | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144) | terminated | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT00288431 | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 22, 2015 | clinicaltrials |
| NCT00779285 | Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) | terminated | Phase 4 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 14, 2015 | clinicaltrials |
| NCT00473889 | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | terminated | Phase 2 / Phase 3 | 253 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 3, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT00365443 | Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 19, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT00099346 | MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) | terminated | Phase 1 | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT00260039 | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | completed | Phase 2 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | completed | Phase 2 | 620 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00724672 | A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) | withdrawn | — | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 1, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00907738 | A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | completed | Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00109538 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | terminated | Phase 3 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 1, 2015 | clinicaltrials |
| NCT01010672 | Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) | completed | Phase 2 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2015 | clinicaltrials |
| NCT00302471 | MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 27, 2015 | clinicaltrials |
| NCT00073450 | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) | terminated | Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT00127101 | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | terminated | Phase 1 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT00771472 | Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT00424775 | A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) | terminated | Phase 1 | 3 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00081510 | Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) | completed | Phase 2 | 110 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 15, 2015 | clinicaltrials |
| NCT00743431 | Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) | completed | — | 224 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 15, 2015 | clinicaltrials |
| NCT01071304 | Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) | completed | Phase 1 | 16 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00496353 | MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) | completed | Phase 1 / Phase 2 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 31, 2015 | clinicaltrials |
| NCT00518739 | MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) | completed | Phase 1 | 25 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 27, 2015 | clinicaltrials |
| NCT00536588 | A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) | completed | Phase 1 | 17 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 27, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00647114 | A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED) | completed | Phase 1 | 41 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2015 | clinicaltrials |
| NCT00325130 | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) | completed | Phase 3 | 1,042 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 12, 2015 | clinicaltrials |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | terminated | Phase 1 / Phase 2 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00122343 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | completed | Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 19, 2015 | clinicaltrials |
| NCT00880568 | Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED) | completed | Phase 1 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 19, 2015 | clinicaltrials |
| NCT00040547 | Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 18, 2015 | clinicaltrials |
| NCT00040534 | Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED) | terminated | Phase 1 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 16, 2015 | clinicaltrials |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00538239 | Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)(SUCCEED) | completed | Phase 3 | 711 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00704054 | A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) | completed | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00781846 | Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | completed | Phase 1 | 17 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00112372 | Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) | completed | Phase 1 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 12, 2015 | clinicaltrials |
| NCT00250419 | V930 First in Man (FIM) Study (V930-002)(COMPLETED) | completed | Phase 1 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT00730379 | A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) | completed | Phase 1 | 87 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT01650727 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | completed | Phase 1 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials